Sucralfate

• Duodenal Ulcers
• Stress Ulcer Prevention
• Peptic Ulcer Disease

Sucralfate (Carafate) is a unique gastrointestinal cytoprotective agent — a basic aluminum salt of sulfated sucrose — that works locally rather than systemically. Instead of suppressing gastric acid the way a proton pump inhibitor like omeprazole or pantoprazole does, sucralfate forms a sticky protective layer over ulcerated mucosa, allowing healing to proceed beneath that barrier. It is used primarily for treatment and maintenance of duodenal ulcers and is widely used off-label for stress ulcer prophylaxis, radiation proctitis, oral mucositis, and bile-reflux gastritis. With less than 5% systemic absorption, it has a strong safety profile but is inconvenient to dose because it must be taken on an empty stomach four times daily and must be separated from many other medications by at least two hours. The advent of potent and well-tolerated proton pump inhibitors has reduced sucralfate's role over the past two decades, but it retains specific niches where its mechanism is uniquely useful.

Mechanism of Action

In the acidic environment of the stomach (pH below 4), sucralfate dissociates into negatively charged sulfated sucrose anions that bind avidly to positively charged proteins exposed at sites of ulcerated or eroded mucosa. The result is a viscous, paste-like coating that selectively adheres to ulcer craters for up to 6 hours, providing a physical barrier against further attack by acid, pepsin, and bile salts. Beyond the simple barrier effect, sucralfate stimulates local prostaglandin synthesis, increases mucus and bicarbonate production, concentrates epidermal and basic fibroblast growth factors at the ulcer base, and binds bile salts that would otherwise damage gastric mucosa in cases of reflux gastritis — all of which accelerate epithelial regeneration. Because it requires acid for activation, sucralfate works best when not co-administered with antacids, proton pump inhibitors, or H2 blockers within the same hour, although clinical practice often combines them with appropriate spacing. Healthy mucosa is largely spared from sucralfate binding because the negatively charged proteins that mediate adherence are exposed only where the protective epithelial barrier has been disrupted.

Clinical Use

Sucralfate is FDA-approved for short-term (up to 8 weeks) treatment of active duodenal ulcer and for maintenance therapy after healing. In modern practice, however, peptic ulcer disease is most often driven by Helicobacter pylori infection or NSAID use, so primary therapy now focuses on H. pylori eradication (typically a PPI plus two antibiotics such as clarithromycin and amoxicillin, or bismuth quadruple therapy) and removal or mitigation of NSAID exposure. Sucralfate is reserved for patients with active ulcers who cannot tolerate or have contraindications to PPI therapy, for stress ulcer prophylaxis in critically ill patients (where it has the advantage of not raising gastric pH and therefore not increasing pneumonia risk the way PPIs may), for radiation-induced mucositis, and as adjunctive therapy in selected cases of GERD with bile reflux. It is also used for esophageal ulcers from pill-induced injury, for oral aphthous ulcers as a topical rinse, and to manage symptoms of certain post-surgical anastomotic ulcers. The American College of Gastroenterology peptic ulcer guideline places sucralfate as a second-line option behind acid suppression for typical ulcer disease. Lifestyle measures — limiting NSAID use, addressing alcohol, smoking cessation, and identifying NSAID-free pain alternatives like acetaminophen or topical diclofenac gel — remain foundational.

How to Take It

Sucralfate is taken as a 1 g tablet or 10 mL of suspension four times daily for active ulcer treatment: one hour before each meal and at bedtime, on a completely empty stomach. The empty-stomach requirement is crucial — food and antacids interfere with the binding to ulcer tissue and reduce efficacy. For maintenance after healing, the dose drops to 1 g twice daily. Swallow tablets whole with water; the suspension should be shaken vigorously before each dose. The tablet is large and can be difficult to swallow, in which case the suspension is preferable. Separate sucralfate from any other oral medication by at least 2 hours, and from antacids by at least 30 minutes — sucralfate's strong binding affinity sharply reduces the absorption of many co-administered drugs (see Monitoring section). The first week often brings constipation as the most noticeable effect; increasing water and fiber intake usually controls it, and a stool softener like docusate can be used if needed. Most ulcers heal within 4-6 weeks, but treatment may continue up to 8 weeks before reassessment. Because sucralfate's mechanism is local rather than systemic, missing a single dose has limited consequence — take the next scheduled dose without doubling.

Monitoring and Follow-Up

Documented symptom relief — resolution of epigastric pain, improvement in dyspepsia, absence of new bleeding — is the main clinical endpoint. Repeat endoscopy is reserved for non-healing ulcers, gastric ulcers (to exclude malignancy via biopsy), or recurrent disease. H. pylori testing should be performed in any patient with peptic ulcer disease and treated if positive; test-of-cure with urea breath test or stool antigen 4 weeks after completing antibiotics confirms eradication. Drug-interaction screening at every visit is essential because sucralfate impairs absorption of fluoroquinolones (such as ciprofloxacin and levofloxacin), tetracyclines like doxycycline, levothyroxine, warfarin, digoxin, phenytoin, furosemide, ketoconazole, and many others — these need at least a 2-hour separation. In patients on long-term sucralfate, especially with chronic kidney disease, periodic serum creatinine and aluminum levels may be warranted because of slow aluminum accumulation that can produce neurotoxicity, encephalopathy, or osteomalacia in advanced cases. Monitor for bezoar formation in critically ill patients receiving enteral feeds plus sucralfate, particularly those with delayed gastric emptying or impaired GI motility.

Special Populations

Use with caution in chronic kidney disease and avoid in dialysis patients when possible because of cumulative aluminum exposure; if used, limit duration and monitor aluminum levels. No specific hepatic dose adjustment is needed. Pregnancy data are limited; minimal systemic absorption suggests low fetal risk, and sucralfate is sometimes selected for GERD or ulcer symptoms in pregnancy when acid-suppressive options are not preferred. Lactation transfer is likely negligible. Pediatric safety has not been formally established, though sucralfate is used in selected pediatric situations under specialist guidance. Older adults are particularly susceptible to constipation and to drug interactions because of polypharmacy — comprehensive medication review at every visit is essential, with attention to anticholinergic burden from co-prescribed agents. Patients with diabetic gastroparesis or other motility disorders may experience worsening symptoms with sucralfate.

When to Contact Your Doctor

Call the office for severe constipation that does not respond to fluids and fiber, signs of GI bleeding (black tarry stools, vomiting blood or coffee-ground material, lightheadedness when standing), persistent abdominal pain that worsens despite treatment, unintended weight loss, difficulty swallowing, or a rash. Patients with renal impairment should report any new neurologic symptoms — confusion, tremor, bone pain, or muscle weakness — that could suggest aluminum toxicity. New or persistent symptoms after an apparently completed course of treatment may suggest H. pylori has not been eradicated or that the ulcer has recurred and warrants repeat evaluation.

A few practical points improve outcomes. The four-times-daily dosing schedule is the most common cause of treatment failure because adherence falls off with each additional daily dose; patients should set phone reminders, link doses to consistent daily activities (waking, mid-morning, late afternoon, bedtime), and plan around meal timing in advance. The suspension formulation is preferable for patients with swallowing difficulty, on tube feeds, or who report difficulty with the large tablet. Avoid carbonated beverages immediately before or after dosing because the acid neutralization may interfere with sucralfate activation. Patients with comorbid GERD who are on a PPI for reflux symptoms can still benefit from sucralfate for esophageal or gastric ulcer healing, but careful timing is needed — most clinicians give the PPI first thing in the morning and the sucralfate doses around meals and at bedtime, with at least 30-60 minutes of separation. Lifestyle factors that predispose to ulcer disease include unmanaged stress, poor sleep, smoking, alcohol use, and chronic NSAID exposure for joint pain — addressing these multiplies the benefit of pharmacologic therapy.

For a thorough evaluation of upper GI symptoms, H. pylori testing, NSAID review, and a tailored ulcer or reflux treatment plan, contact us or schedule a visit at Zimmer Medical Group.